Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989834 | 0.90 | SIRT1 (0.52) | SIRT1NR1H4ATMMAPTL3MBTL1 | |
| SCHEMBL2989948 | 0.85 | SIRT1 (0.49) | SIRT1NR1H4MAPTL3MBTL1KDM4E | |
| SCHEMBL2975672 | 0.83 | SIRT1 (0.62) | SIRT1NR1H4ATMMAPT | |
| SCHEMBL2977798 | 0.82 | SIRT1 (0.57) | SIRT1NR1H4ATML3MBTL1CASP3 | |
| SCHEMBL2992188 | 0.81 | SIRT1 (0.56) | SIRT1NR1H4ATMMAPTL3MBTL1 | |
| SCHEMBL2982976 | 0.81 | SIRT1 (0.60) | SIRT1NR1H4ATMMAPT | |
| SCHEMBL2988617 | 0.81 | NR1H4 (0.68) | SIRT1NR1H4ATM | |
| SCHEMBL2989807 | 0.80 | SIRT1 (0.61) | SIRT1NR1H4ATMMAPT | |
| SCHEMBL2980137 | 0.80 | SIRT1 (0.55) | SIRT1NR1H4ATML3MBTL1CASP3 | |
| SCHEMBL2984134 | 0.80 | SIRT1 (0.55) | SIRT1NR1H4ATML3MBTL1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | claimed |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | disclosed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | SIRT1 2093/4885NR1H4 4747/4885ATM 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.